In Cohort 1, for patients designing to have high dose (2.37x10^11 vg), sequential enrollment will be applied. The patients need to be followed for 2 months or more until the severity of post-gene therapy dyskinesia decreases, judged by a decrease in dose of drugs used to decrease dyskinesia or an improvement in feeding. After the agreement of the Safety Committee, the next high-dose patient can be enrolled. In Cohort 2, only patients older than or equal to 3 years need sequential enrollment.